Trustees

Trustees

Management

Closed-End Funds

Jeffrey A. Bailey

Board Chairperson (since 2022), HQH, HQL, THQ and THW Trustee (since 2020); CEO, IlluminOss Inc. (2018 to 2020); Vice President, Janssen Pharmaceutica (Johnson & Johnson) (1984-2006); Board Chairperson, Aileron Therapeutics Inc. (since 2018); Director, Madison Vaccines, Inc. (since 2018); Director and CEO, BioDelivery Systems, Inc. (2020 to 2022).

Kathy L. Goetz

Trustee, HQH, HQL, THQ and THW (since 2021); Consultant (Since 2020); Novartis Pharmaceuticals: Vice President and Head of Sales (2017-2019), Executive Director of Strategic Account Management (2015-2016), Regional Sales Director - Neuroscience Business Unit (2012-2015), Marketing Brand Director - Reclast (2011), Ad Interim General Manager (2010), Managing Sales Director (2008-2010) and Integrated Markets, Strategic Planning (2007-2008).

Rakesh K. Jain, PhD

Trustee, HQH, HQL (since 2007), THQ (since 2014) and THW (since 2015); Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (2012-2018).

Thomas M. Kent, CPA

Trustee, HQH, HQL, THQ and THW (since 2017); Partner, PricewaterhouseCoopers LLP (1989-2013); Director, Principal Global Investors Trust Co. (since 2014); Director, Thayer Academy (2009-2018); Director, New England Canada Business Council (since 2017).

Daniel R. Omstead, PhD *

Trustee, HQH, HQL (since 2003), THQ (since 2014) and THW (since 2015); President, HQH, HQL (since 2001), THQ (since 2014) and THW (since 2015); Chief Executive Officer and Managing Member, Tekla Capital Management LLC (since 2002).

W. Mark Watson, CPA

Trustee, (since 2022); Partner, Deloitte & Touche LLP (1973-2013); Director, BioDelivery Sciences International, Inc. (2017-2022); Director, Inhibitor Therapeutics, Inc. (since 2014); Director, Global Health MCS, (since 2014); Director, Sykes Enterprises, Inc. (2018-2021); Director, The Moffitt Cancer Center (since 2009).

* Trustee considered to be an “interested person” within the meaning of the Investment Company Act of 1940, as amended, through a position or affiliation with Tekla Capital Management LLC.

 

© 2023 Tekla Capital Management LLC | All rights reserved | Legal Disclaimer

The material contained on this website is not intended to be a recommendation or investment advice, does not constitute a solicitation to buy or sell securities, and is not provided in a fiduciary capacity. The information provided does not take into account the specific objectives or circumstances of any particular investor, or suggest any specific course of action. Investment decisions should be made based on an investor’s objectives and circumstances and in consultation with his or her advisors.

There can be no assurance that any closed-end fund will achieve its investment objective(s). Past performance does not guarantee future results. The net asset value of any closed-end fund will fluctuate with the value of the underlying securities. Historically closed-end funds have often traded at a discount to their net asset value. The distribution rate and income amounts reflect past amounts distributed and may not be indicative of future rates or income amounts. Distribution rates and income amounts can change at any time.

Investors should consider the investment objective and policies, risk considerations, charges and ongoing expenses of an investment carefully before investing. For more information, please contact your marketing and distribution agent, Destra Capital Advisors LLC at 877.855.3434.

NOT FDIC-INSURED | NOT BANK-GUARANTEED | MAY LOSE VALUE

social sharing image for Tekla Capital Management LLC website